MG Symptoms PRO Highlights Rozanolixizumab’s Impact on Fatigue, Weakness

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan and the European Union following later that year and 2025, respectively.